Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death

Clinical Infectious Diseases

Volumn 46, Issue 10, 2008, Pages 1626-1627

  Cornely, Oliver A ^a   Ullmann, Andrew J ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; ANTIFUNGAL AGENT; TRIAZOLE DERIVATIVE;

ASPERGILLOSIS; COST BENEFIT ANALYSIS; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; LETTER; MYCOSIS; NEUTROPENIA; PRIORITY JOURNAL; RISK ASSESSMENT; CHEMOPROPHYLAXIS; ECONOMICS; NOTE;

ANTIFUNGAL AGENTS; CHEMOPREVENTION; HUMANS; MYCOSES; TRIAZOLES;

EID: 43249126048     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/587177     Document Type: Letter

References (6)

1. Nagappan V, Deresinski S. Posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007; 45:1610-7.
2. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356:348-59.
3. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356:335-47.
4. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995; 310:452-4.
5. de Pauw BE, Donnelly JP. Prophylaxis and aspergillosis - has the principle been proven? N Engl J Med 2007; 356:409-11.
6. Sinclair JC, Cook RJ, Guyatt GH, Pauker SG, Cook DJ. When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment. J Clin Epidemiol 2001; 54: 253-62.